推进CAR-T细胞治疗系统性红斑狼疮的关键考量:多伙伴跨学科工作组视角
Lupus Accelerating Breakthroughs Consortium召集学术界/临床医生、产业代表、监管者和狼疮患者的多伙伴工作组,讨论CAR-T治疗SLE的临床开发考量。工作组审视了入组标准风险/获益、早期剂量与剂量限制性毒性、晚期注册试验对照臂、SLE特异性预处理与免疫监测及临床前模型局限,并提出未来行动呼吁。
要点
- 工作组认为CAR-T治疗SLE需基于严重度/难治性定义入组标准。
- 晚期注册试验设计需考虑纳入对照臂。
- 需建立长期监测基础设施并为风湿科医生和患者提供教育与后勤支持。
核心结论
- 早期数据显示CAR-T细胞疗法有潜力扩展系统性红斑狼疮的治疗格局。
- 工作组就SLE特异性临床开发问题提出未来行动呼吁,包括定义基于严重度/难治性的入组标准、长期监测基础设施及对风湿科医生和患者的教育与后勤支持。
研究设计与样本
- Lupus Accelerating Breakthroughs Consortium(公私合作伙伴关系)召集多伙伴工作组,成员包括学术界/临床医生(含风湿科医生和肿瘤科医生)、产业代表(含SLE及CAR-T临床开发专家)、监管者和狼疮患者。
主要发现
- 工作组讨论了狼疮入组标准的风险/获益考量、早期阶段给药与剂量限制性毒性挑战、晚期注册试验设计中纳入对照臂、SLE特异性预处理治疗与免疫监测问题及SLE临床前模型研究细胞疗法的局限性。
临床怎么用
- 原文未述临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early data have shown the potential of chimeric antigen receptor (CAR) T-cell therapies to expand the therapeutic landscape in systemic lupus erythematosus (SLE). While many CAR T-cell therapy learnings can be drawn from the experience of this modality in oncology, key questions remain regarding clinical development considerations unique to lupus. To assess and discuss these issues, the Lupus Accelerating Breakthroughs Consortium, a public-private partnership, convened a multi-partner working group to collect the diverse perspectives of academics/clinicians (including rheumatologists and oncologists), industry representatives (including SLE as well as CAR T-cell clinical development experts), regulators and people living with lupus on this potentially ground-breaking therapy. The working group considered the risk/benefit considerations for eligibility criteria in lupus, early-phase dosing and dose-limiting toxicity challenges, incorporation of comparator arms in late-phase registrational trial design, SLE-specific issues in conditioning therapy and immune monitoring and the limitations of SLE pre-clinical models for studying cell therapies. The key future 'calls to action' for the field include the need for well-defined severity/refractoriness-based eligibility criteria, the need for long-term monitoring infrastructure and the need for educational and logistical support for rheumatologists and patients.
引用
- Hsieh EWY, Chung JB, Amin A, et al. Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective. RMD Open. 2025. PMID: 41052891. doi:10.1136/rmdopen-2025-005866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。